Fast Track Designation

Fast track, added by the FDA Modernization Act of 1997 and now sitting in section 506(b), applies to a drug intended to treat a serious condition where nonclinical or clinical data demonstrate the potential to address an unmet medical need. The bar is deliberately low and early: unlike breakthrough designation, a request can be granted on animal data alone, and it can be filed alongside the original investigational new drug application.

The benefits are procedural. More frequent meetings and written communication with the review division, and rolling review, in which completed sections of an application are submitted as they are finished rather than all together at the end. Designation also makes a product eligible to be considered for accelerated approval and for priority review, though each of those is judged separately against its own criteria at the time it is sought.

As a signal about a compound, fast track is close to the weakest of the expedited programmes. Designations are granted in large numbers and many drugs carrying one never file an application at all. It records that a sponsor made a case about unmet need at a stage when almost nothing about efficacy is known, and the designation itself embeds no efficacy finding whatever.

The distortion shows up in company announcements, where fast track is reported with the cadence of a regulatory win. Two errors follow from that framing: reading it as faster approval, when the review clock is set by priority review status rather than by fast track, and reading it as agency endorsement of the drug, when FDA has committed only to talking more often.